Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as a tablet for oral use. It is employed for the prevention of malaria and for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum in travelers and residents of endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial agent used in both prophylaxis and therapy of malaria infections. - Prevention of malaria: provides chemoprophylaxis for travelers to endemic regions. - Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears parasitic infection in diagnosed patients. - Chemoprophylaxis for non‑immune individuals residing temporarily in endemic areas: reduces risk of infection during short‑term exposure.

Malarone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: occasional cramping or discomfort. - Vomiting: occasional expulsion of stomach contents. - Loss of appetite: reduced desire to eat. - Metallic taste: altered taste sensation.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: signs of liver dysfunction including jaundice. - Hemolytic anemia: especially in patients with G6PD deficiency. - Severe hypersensitivity: including anaphylaxis. - Significant neutropenia: marked reduction in white blood cells.

Before prescribing Malarone, clinicians should consider several safety aspects. - Pregnancy: consult a healthcare provider; safety data are limited. - Breastfeeding: weigh potential benefits against possible risks to the infant. - Renal impairment: dose adjustment may be required in severe kidney dysfunction. - Known drug resistance: avoid use in regions with documented atovaquone‑proguanil resistance. - Concomitant medications: review for potential interactions that may affect efficacy or safety. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Malarone can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Rifampin: induces metabolism and markedly reduces atovaquone plasma levels. - Protease inhibitors (e.g., ritonavir): may increase atovaquone concentrations, raising toxicity risk. - St. John’s wort: induces hepatic enzymes, decreasing drug exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may lower atovaquone absorption; separate dosing by at least 2 hours. - Warfarin: potential increase in INR; monitor coagulation parameters. - Cimetidine: can raise atovaquone levels; observe for enhanced side effects.